News

FDA decision changes scope of healthcare delivery; increases patient access to early detection of DR

Fifteen fellows, residents showed just why research in retina is on the cutting edge

Investigators optimistic about sustained-release ranibizumab delivery based on phase II LADDER study

Patrik De Haes, MD, CEO of Oxurion NV, shares the latest updates in clinical studies at the OIS@AAO meeting in Chicago, Oct. 2018.

Patients tolerate therapy well; high safety profile allows re-treatment as necessary

A better understanding of the pathophysiologic mechanisms of diabetes has resulted in improved control of its local and systemic comorbidities. Further developments are needed, however, considering the growing number of diabetic patients and who are at risk for late-stage diabetic eye disease.

Research finds limited publications and dearth of information about side effects

Findings from the PERMEATE study used novel diagnostics to quantify response to intravitreal injections